Literature DB >> 20466522

Association of NPAS3 exonic variation with schizophrenia.

Georgina Macintyre1, Tyler Alford, Lan Xiong, Guy A Rouleau, Philip G Tibbo, Diane W Cox.   

Abstract

BACKGROUND: We previously identified the neuronal PAS3 (NPAS3) gene as a candidate gene for schizophrenia. A mother and daughter, both with schizophrenia, were carriers of a translocation, t(9;14)(q34;q13), that disrupts the NPAS3 gene. The gene is located at 14q13, a region implicated in schizophrenia and bipolar disorder in various linkage studies. NPAS3 belongs to the basic helix-loop-helix Per-Arnt-Sim (bHLH-PAS) transcription factor family, involved in diverse processes including the regulation of cell differentiation and circadian rhythms, and the development and function of the nervous system.
METHODS: The 12 exons encoding NPAS3 were sequenced in DNA from individuals with schizophrenia. NPAS3 variants were identified in exons 6 and 12, initially in 12 patients only. These two exons were then sequenced in 83 patients and 83 controls. RESULTS AND
CONCLUSION: Three common variants of NPAS3, also found in controls, showed a positive association with schizophrenia (NM_001164749: rs12434716, c.1654G>C, p=0.009; rs10141940, c.2208C>T, p=0.01; rs10142034, c.2262C>G, p=0.01). The c.1654G>C variant, results in an p.Ala552Pro change and may affect NPAS3 protein function directly. Alternatively, the three SNPs may affect the splicing of NPAS3 transcripts, as they are each located within putative exonic splicing enhancer (ESE) motifs (ESEFinder). A c.726C>T variant, identified in three patients, is located in an ESE element and is predicted to reduce the function of the motif. Other variants, identified in controls, included c.2089G>A (p.Gly697Ser) and c.2097T>C. Our identification of potentially defective NPAS3 variants supports recent studies that implicate perturbations in NPAS3 pathways in impaired neurogenesis and psychosis. (c) 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20466522     DOI: 10.1016/j.schres.2010.04.002

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  19 in total

1.  Electrophysiological, transcriptomic and morphologic profiling of single neurons using Patch-seq.

Authors:  Cathryn R Cadwell; Athanasia Palasantza; Xiaolong Jiang; Philipp Berens; Qiaolin Deng; Marlene Yilmaz; Jacob Reimer; Shan Shen; Matthias Bethge; Kimberley F Tolias; Rickard Sandberg; Andreas S Tolias
Journal:  Nat Biotechnol       Date:  2015-12-21       Impact factor: 54.908

2.  A mutation in NPAS3 segregates with mental illness in a small family.

Authors:  L Yu; N Arbez; L G Nucifora; G L Sell; L E Delisi; C A Ross; R L Margolis; F C Nucifora
Journal:  Mol Psychiatry       Date:  2013-01-22       Impact factor: 15.992

3.  NPAS3 demonstrates features of a tumor suppressive role in driving the progression of Astrocytomas.

Authors:  Frederico Moreira; Tim-Rasmus Kiehl; Kelvin So; Norbert F Ajeawung; Carmelita Honculada; Peter Gould; Russell O Pieper; Deepak Kamnasaran
Journal:  Am J Pathol       Date:  2011-05-19       Impact factor: 4.307

4.  Cross-disorder analysis of bipolar risk genes: further evidence of DGKH as a risk gene for bipolar disorder, but also unipolar depression and adult ADHD.

Authors:  Heike Weber; Sarah Kittel-Schneider; Alexandra Gessner; Katharina Domschke; Maria Neuner; Christian P Jacob; Henriette N Buttenschon; Andrea Boreatti-Hümmer; Julia Volkert; Sabine Herterich; Bernhard T Baune; Silke Gross-Lesch; Juliane Kopf; Susanne Kreiker; Thuy Trang Nguyen; Lena Weissflog; Volker Arolt; Ole Mors; Jürgen Deckert; Klaus-Peter Lesch; Andreas Reif
Journal:  Neuropsychopharmacology       Date:  2011-06-08       Impact factor: 7.853

5.  Neuronal PAS Domain Proteins 1 and 3 Are Master Regulators of Neuropsychiatric Risk Genes.

Authors:  Jacob J Michaelson; Min-Kyoo Shin; Jin-Young Koh; Leo Brueggeman; Angela Zhang; Aaron Katzman; Latisha McDaniel; Mimi Fang; Miles Pufall; Andrew A Pieper
Journal:  Biol Psychiatry       Date:  2017-04-06       Impact factor: 13.382

6.  Discovery of a proneurogenic, neuroprotective chemical.

Authors:  Andrew A Pieper; Shanhai Xie; Emanuela Capota; Sandi Jo Estill; Jeannie Zhong; Jeffrey M Long; Ginger L Becker; Paula Huntington; Shauna E Goldman; Ching-Han Shen; Maria Capota; Jeremiah K Britt; Tiina Kotti; Kerstin Ure; Daniel J Brat; Noelle S Williams; Karen S MacMillan; Jacinth Naidoo; Lisa Melito; Jenny Hsieh; Jef De Brabander; Joseph M Ready; Steven L McKnight
Journal:  Cell       Date:  2010-07-09       Impact factor: 41.582

7.  NPAS1 represses the generation of specific subtypes of cortical interneurons.

Authors:  Amelia Stanco; Ramón Pla; Daniel Vogt; Yiran Chen; Shyamali Mandal; Jamie Walker; Robert F Hunt; Susan Lindtner; Carolyn A Erdman; Andrew A Pieper; Steven P Hamilton; Duan Xu; Scott C Baraban; John L R Rubenstein
Journal:  Neuron       Date:  2014-11-20       Impact factor: 17.173

8.  Copy number variation analysis implicates the cell polarity gene glypican 5 as a human spina bifida candidate gene.

Authors:  Alexander G Bassuk; Lakshmi B Muthuswamy; Riley Boland; Tiffany L Smith; Alissa M Hulstrand; Hope Northrup; Matthew Hakeman; Jason M Dierdorff; Christina K Yung; Abby Long; Rachel B Brouillette; Kit Sing Au; Christina Gurnett; Douglas W Houston; Robert A Cornell; J Robert Manak
Journal:  Hum Mol Genet       Date:  2012-12-07       Impact factor: 6.150

9.  Evidence for shared genetic risk between methamphetamine-induced psychosis and schizophrenia.

Authors:  Masashi Ikeda; Yuko Okahisa; Branko Aleksic; Mujun Won; Naoki Kondo; Nobuya Naruse; Kumi Aoyama-Uehara; Ichiro Sora; Masaomi Iyo; Ryota Hashimoto; Yoshiya Kawamura; Nao Nishida; Taku Miyagawa; Masatoshi Takeda; Tsukasa Sasaki; Katsushi Tokunaga; Norio Ozaki; Hiroshi Ujike; Nakao Iwata
Journal:  Neuropsychopharmacology       Date:  2013-04-12       Impact factor: 7.853

10.  Targeted pharmacogenetic analysis of antipsychotic response in the CATIE study.

Authors:  Qian Liu; Maidar Jamba; Calvin Patrick; Saranya Padmanabhan; Mark D Brennan
Journal:  Pharmacogenomics       Date:  2012-08       Impact factor: 2.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.